Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SORD | Q00796 | 1/20 | 0.57 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7432371 | 0.89 | HTR3A (0.74) | HTR3AKMT2A | |
| SCHEMBL17417624 | 0.86 | HTR3A (0.73) | HTR3A | |
| SCHEMBL16649554 | 0.85 | KMT2A (0.68) | KMT2ASORD | |
| SCHEMBL9212633 | 0.83 | HTR3A (0.66) | HTR3A | |
| Lerisetron SCHEMBL141124 | 0.83 | HTR3A (1.00) | HTR3ASOS1 | |
| Lerisetron SCHEMBL30669539 | 0.83 | HTR3A (1.00) | HTR3ASOS1 | |
| Lerisetron SCHEMBL29040939 | 0.82 | HTR3A (0.97) | HTR3ASOS1 | |
| SCHEMBL2709699 | 0.81 | HTR3A (0.63) | HTR3AKMT2A | |
| SCHEMBL6596582 | 0.81 | HTR3A (0.66) | HTR3A | |
| Iodide SCHEMBL7628527 | 0.80 | HTR3A (0.65) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | claimed |
| EP-0512939-B1 | 2-piperazinylbenzimidazole derivatives | ESPANOLA PROD QUIMICOS (ES) | 1999-08-25 | — | — | EP | claimed |
| US-5256665-A | Process for preparing new 2-piperazinylbenzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1993-10-26 | — | — | US | claimed |
| EP-0512939-A1 | New 2-piperazinylbenzimidazole derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-11-11 | — | — | EP | claimed |
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | disclosed |
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1255736-A2 | SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | Boehringer Ingelheim Pharma KG (DE) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001047898-A2 | SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | disclosed |
| EP-0512939-B1 | 2-piperazinylbenzimidazole derivatives | ESPANOLA PROD QUIMICOS (ES) | 1999-08-25 | — | — | EP | disclosed |
| US-5256665-A | Process for preparing new 2-piperazinylbenzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1993-10-26 | — | — | US | disclosed |
| EP-0512939-A1 | New 2-piperazinylbenzimidazole derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | HTR3A 2835/4885KMT2A 3314/4885SORD 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.